

COV-COMPARE: A study to compare the VLA2001 and AZD1222 vaccines against COVID-19 in adults

Submission date 26/04/2021	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 27/04/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 07/06/2021	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

COVID-19 is a condition caused by the coronavirus (called SARS-CoV-2) that was first identified in late 2019. This virus can infect the respiratory (breathing) system. Some people do not have symptoms but can carry the virus and pass it on to others. People who have developed the condition may develop a fever and/or a continuous cough among other symptoms. This can develop into pneumonia. Pneumonia is a chest infection where the small air pockets of the lungs, called alveoli, fill with liquid and make it more difficult to breathe.

Valneva's COVID-19 vaccine candidate is called VLA2001. The aim of this study is to compare the immune response to the VLA2001 vaccine to the AZD1222 vaccine in adults aged 30 and older, and to evaluate the safety and tolerability of VLA2001 in adults aged 18 and older.

Who can participate?

Adults aged 18 and older who have not received any COVID-19 vaccination yet, regardless of whether they had been infected by SARS-CoV-2 before or not. Please visit <https://www.ukcovid19study.com> for more information.

What does the study involve?

Participants are randomly allocated to receive either the VLA2001 or AZD1222 vaccine. The participants and treating doctors will not know which of the two vaccines will have been given. The aim is to compare the immune response and safety of the two vaccines, and to establish a robust safety database for VLA2001. Participants will receive VLA2001 at the dose selected based on the results of the first study. The vaccination schedule will be aligned between the two vaccines, i.e. vaccinations will occur on Days 1 and 29, and follow-up visits will be conducted for 1 year.

What are the possible benefits and risks of participating?

This is the second study in human participants and the clinical benefits of VLA2001 have not yet been established. Although the vaccine might induce immune responses that may be protective, participants might not experience any direct benefit from taking part in this study. The information obtained from this study may help prevent future participants from contracting

COVID-19 and will provide important information about how well people respond to VLA2001. There may be risks to being in this study from the study vaccine or from some of the procedures or tests carried out in this study.

Where is the study run from?
Valneva (Austria)

When is the study starting and how long is it expected to run for?
July 2020 to June 2022

Who is funding the study?
Department of Health and Social Care (UK)

Who is the main contact?
Christian Taucher
VLA2001-301@valneva.com

Contact information

Type(s)
Scientific

Contact name
Mr Christian Taucher

Contact details
Campus Vienna Biocenter 3
Vienna
Austria
1030
+43 (0)1 206 20 2020
VLA2001-301@valneva.com

Additional identifiers

Clinical Trials Information System (CTIS)
2021-000522-97

Integrated Research Application System (IRAS)
294164

Protocol serial number
VLA2001-301, IRAS 294164

Study information

Scientific Title
A randomized, observer-blind, controlled, superiority study to compare the immunogenicity against COVID-19 of the VLA2001 vaccine and the AZD1222 vaccine in adults

Acronym

COV-COMPARE

Study objectives

The purpose of this study is to compare the immunogenicity of the VLA2001 vaccine to the AZD1222 vaccine in adults aged 30 years and older; and to evaluate the safety and tolerability of VLA2001 in adults aged 18 years and older.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 20/04/2021, North West - Greater Manchester South Research Ethics Committee (3rd Floor, Barlow House, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8221, +44 (0) 207 104 8063; gmsouth.rec@hra.nhs.uk), REC ref: 21/NW/0125

Study design

Randomized observer-blind controlled superiority Phase III study

Primary study design

Interventional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

COVID-19 (SARS-CoV-2 infection)

Interventions

About 3000 participants aged 30 years and above will be randomized via an Interactive Response System (IRS) in a 2:1 ratio to receive two intramuscular recommended doses of either VLA2001 (n=2000) or AZD1222 (n=1000). In addition, approximately 1000 subjects aged 18-29 years will participate in this study in a non-randomized, open-label fashion to receive VLA2001. The two doses of vaccination for both vaccines will be administered 28 days apart on Days 1 and 29.

Participants will be followed up in the study for approximately 11 months after their second vaccination.

Intervention Type

Biological/Vaccine

Phase

Phase III

Drug/device/biological/vaccine name(s)

VLA2001, AZD1222

Primary outcome(s)

Immunogenicity:

1. Immune response after completion of a two-dose immunization schedule, as determined by the geometric mean titer (GMT) of SARS-CoV-2-specific neutralizing antibodies measured using a neutralization assay on Day 43

Safety:

2. Frequency and severity of any Adverse Events (AE) collected during study visits up to Day 43 post-vaccination

Key secondary outcome(s)

Immunogenicity:

1. Proportion of participants with seroconversion measured using a neutralization assay on Day 8 (age 55+ only), Day 29, Day 43, Day 71, Day 208 and Day 365
2. Immune response, as determined by the GMT of SARS-CoV-2-specific neutralizing antibodies measured using a neutralization assay on Day 8 (age 55+ only), Day 29, Day 71, Day 208 and Day 365
3. Immune response, as determined by the GMT of IgG antibodies to SARS-CoV-2 S-protein measured using an Enzyme-Linked Immunosorbent Assay (ELISA) on Day 8 (age 55+ only), Day 29, Day 43, Day 71, Day 208 and Day 365
4. T-cell responses assessed using T-spot assay and/or intracellular cytokine staining at selected timepoints (yet to be defined) in a subset of participants

Safety:

5. Frequency and severity of solicited injection site and systemic reactions captured using electronic diaries within 7 days after each and after any vaccination
6. Frequency and severity of any AE collected during study visits during the entire study period
7. Frequency and severity of any unsolicited AE collected during study visits until Day 43
8. Frequency and severity of any unsolicited vaccine-related AE collected during study visits until Day 43
9. Frequency and severity of any serious adverse event (SAE) collected during study visits during the entire study period
10. Frequency and severity of any adverse event of special interest (AESI) collected during study visits during the entire study period

Completion date

30/06/2022

Eligibility

Key inclusion criteria

1. Participants must have read, understood, and signed the informed consent form (ICF)
2. Participants of either gender aged 18 years and older at screening
3. Medically stable
4. Must be able to attend all visits of the study and comply with all study procedures
5. Women of childbearing potential (WOCBPs) must be able and willing to use at least one highly effective method of contraception for a minimum of 3 months after the last dose of study vaccine
6. WOCBPs must have a negative pregnancy test prior to each vaccination

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Participant is pregnant or planning to become pregnant within 3 months after study vaccine administration
2. History of allergy to any component of the vaccine
3. Significant infection (e.g. positive SARS-CoV-2 RT-PCR) or other acute illness, including fever >100 °F (>37.8 °C) 48 hours before vaccination
4. Participant has a known or suspected defect of the immune system
5. Participant has a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome
6. Participant has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. If there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the participant may be enrolled. A history of hematologic malignancy is a permanent exclusion. Participants with a history of skin cancer must not be vaccinated at the previous tumour site
7. History of drug dependency or current use of drug abuse or alcohol abuse at screening
8. Significant blood loss (> 450 ml) or has donated one or more units of blood or plasma within 6 weeks prior to the expected day of randomization (Visit 1)
9. History of clinically significant bleeding disorder, or prior history of significant bleeding or bruising following IM injections or venepuncture
10. Severe and uncontrolled ongoing autoimmune or inflammatory disease History of Guillain-Barre syndrome or any other demyelinating condition
11. Any other significant disease, disorder or finding which in the opinion of the investigator may significantly increase the risk to the volunteer

Prior/concomitant therapy:

12. Receipt of immunoglobulin or another blood product within the 3 months before expected day of randomization (visit 1) in this study or those who expect to receive immunoglobulin or another blood product during this study
13. Receipt of medications and or vaccinations intended to prevent COVID-19
14. Receipt of any vaccine (licensed or investigational), other than licensed influenza vaccine, within 28 days prior to the expected day of randomization (Visit 1)

Others:

15. Any member of the study team or sponsor
16. An immediate family member or household member of the study's personnel

Date of first enrolment

28/04/2021

Date of final enrolment

03/06/2021

Locations**Countries of recruitment**

United Kingdom

England

Scotland

Study participating centre**University Hospitals Bristol and Weston NHS Foundation Trust**

Clinical Research Facility

60 St Michaels Hill

Bristol

United Kingdom

BS2 8DX

Study participating centre**University Hospitals Birmingham NHS Foundation Trust**

Mindelsohn Way

Edgbaston

Birmingham

United Kingdom

B15 2WB

Study participating centre**The Newcastle upon Tyne Hospitals NHS Foundation Trust**

Freeman Hospital Newcastle

Level 6, Leazes Wing

Royal Victoria Infirmary

Queen Victoria Road

Newcastle

United Kingdom

NE1 4LP

Study participating centre**Southampton University Hospitals NHS Trust**

Tremona Road

Southampton
United Kingdom
SO16 6YD

Study participating centre

University Hospital Plymouth NHS Trust

1 Roscoff Rise
Derriford
Level 2
MSCP
Bircham Park Offices
Plymouth
United Kingdom
PL6 5FP

Study participating centre

St George's University Hospitals NHS Foundation Trust

Room 0.160, Level 0
Jenner Wing, St George's
Cranmer Terrace
London
United Kingdom
SW17 0RE

Study participating centre

Chelsea and Westminster Hospital NHS Trust

369 Fulham Road
Chelsea
London
United Kingdom
SW10 9NH

Study participating centre

NIHR UCLH Clinical Research Facility

4th Floor
170 Tottenham Court Road
London
United Kingdom
W1T 7HA

Study participating centre

Royal Free London NHS Foundation Trust

Pond St
London
United Kingdom
NW3 2QG

Study participating centre

Cambridge Biomedical Research Centre

Hills Road
Cambridge
United Kingdom
CB2 0QQ

Study participating centre

University Hospitals Coventry & Warwickshire

Clifford Bridge Road
Walsgrave
Coventry
United Kingdom
CV2 2DX

Study participating centre

Lakeside Healthcare Research

2nd Floor Urgent Care (UC) Building
Cottingham Road
Corby
Northampton
United Kingdom
NN17 2UR

Study participating centre

Nottingham University Hospitals NHS Trust

B Floor, Medical School
Queen's Medical Centre Campus
Derby Road
Nottingham
United Kingdom
NG5 1PB

Study participating centre

NHS Foundation Trust Royal Liverpool University Hospital

2nd Floor
Prescott Street
Liverpool
United Kingdom
L7 8XP

Study participating centre

Northern Care Alliance NHS Group, Salford Royal NHS Foundation Trust

Stott Lane
Salford
United Kingdom
M6 8HD

Study participating centre

Barnsley Hospital NHS Foundation Trust

Lock 14
Gawber Road
Barnsley
United Kingdom
S75 2EP

Study participating centre

Blackpool Teaching Hospitals NHS Foundation Trust

Whinney Heys Road
Blackpool
United Kingdom
FY3 8NR

Study participating centre

Northumbria Healthcare NHS Foundation Trust

North Tyneside General Hospital
Rake Lane
North Shields
United Kingdom
NE29 8NH

Study participating centre

Queen Elizabeth University Hospital

Glasgow Clinical Research Facility
5th Floor

1345 Govan Road
Glasgow
United Kingdom
G51 4TF

Study participating centre

Panthera London
Enfield 1 Woodall Road
London
United Kingdom
EN3 4GS

Study participating centre

Panthera Biopartners Manchester
610 Bury Rd
Rochdale
United Kingdom
OL11 4AU

Study participating centre

Panthera Biopartners Preston
73 St Gregory Road
Preston
United Kingdom
PR1 6YA

Study participating centre

Royal Surrey County Hospital NHS Foundation Trust
Egerton Road
Guildford
United Kingdom
GU2 7XX

Study participating centre

Cheadle Community Hospital
Research Unit
Ward 3
Royal Walk
Cheadle
United Kingdom
ST10 1NS

Study participating centre
Western General Hospital, Edinburgh – NHS Lothian
Crewe Rd S
Edinburgh
United Kingdom
EH4 2XU

Study participating centre
North Bristol NHS Trust
Southmead Rd
Bristol
United Kingdom
BS10 5NB

Sponsor information

Organisation
Valneva (Austria)

ROR
<https://ror.org/03xk4a758>

Funder(s)

Funder type
Government

Funder Name
Department of Health and Social Care

Alternative Name(s)
Department of Health & Social Care, DH

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The current data-sharing plans for this study are unknown and will be available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes